Necroptosis and Tumor Immunity: The RIPK1–RIPK3–MLKL Axis, ZBP1 Signaling, and Experimental Determination

Necroptosis is a form of regulated cell death centered on the RIPK3–MLKL execution axis. Plasma membrane rupture can be accompanied by the release of DAMPs, tumor antigens, and inflammatory signals, thereby directly linking cell death to changes in the tumor immune microenvironment. RIPK1-dependent signaling, ZBP1-mediated noncanonical RIPK3 activation, and pre-death inflammatory transcription jointly determine its immune output, whereas different cell types and microenvironmental contexts can confer either antitumor or protumor effects on necroptosis.

Keywords: necroptosis; RIPK1; RIPK3; MLKL; ZBP1; tumor immunity; immunogenic cell death; immune checkpoint blockade

1 Molecular Basis of Necroptosis

1.1 Differences from Other Forms of Cell Death

Necroptosis belongs to regulated cell death (RCD). Its terminal stage can involve cell swelling, organelle swelling, loss of plasma membrane integrity, and release of intracellular contents, producing necrosis-like features. However, because its execution is controlled by molecules such as RIPK3 and MLKL, it differs from accidental necrosis caused by mechanical injury or extreme physicochemical stress. Classical apoptosis mainly depends on caspase cascades, and plasma membrane integrity is generally maintained during the early stage; pyroptosis mainly depends on Gasdermin-mediated pore formation. The core characteristic of necroptosis is not simply “cell rupture,” but a regulated execution chain linking RIPK3 activation, MLKL phosphorylation, and membrane damage.

Table 1 Major Differences Among Apoptosis, Necroptosis, Pyroptosis, and Unregulated Necrosis

Cell Death Type	Core Molecules	Plasma Membrane Changes	Representative Molecular Readouts	Inflammatory Property
Apoptosis	caspase-8/9, caspase-3/7, BAX/BAK	Intact at early stages; secondary rupture may occur later	cleaved caspase-3, cleaved PARP	Usually relatively low
Necroptosis	RIPK1, RIPK3, MLKL	Loss of integrity after MLKL activation	p-RIPK3, p-MLKL	Relatively strong
Pyroptosis	inflammasome, caspase-1/4/5, GSDMD	Rupture after Gasdermin pore formation	cleaved GSDMD, caspase-1, IL-1β	Strong
Unregulated necrosis	No unified specific execution axis	Direct rupture	Nonspecific death indicators such as LDH and PI	Depends on injury severity

1.2 RIPK1–RIPK3–MLKL Execution Axis

(1) RIPK1-Dependent Initiation

TNF/TNFR1 is one of the classical necroptosis signaling pathways. Following TNFR1 activation, RIPK1 first participates in receptor-proximal signaling regulation. When caspase-8 activity is inhibited, the ubiquitination state of RIPK1 changes, or prosurvival signaling is restricted, RIPK1 kinase activity can promote formation of death complexes and recruit RIPK3 through RHIM-mediated interactions, shifting cells from survival- or apoptosis-related signaling toward the necroptosis program.

(2) RIPK3 Activation

RIPK3 is a key kinase in the necroptosis execution program, but its activation is not absolutely dependent on RIPK1. In addition to the TNF-related RIPK1–RIPK3 pathway, ZBP1 can directly connect to RIPK3 through RHIM interactions, while TLR3/TLR4-related TRIF signaling can also enter the RIPK3 node. RIPK3 therefore serves as a central hub through which multiple upstream stress and innate immune signals converge on the necroptosis execution program.

(3) MLKL Phosphorylation and Membrane Rupture

After activated RIPK3 phosphorylates MLKL, MLKL undergoes conformational changes, oligomerization, and redistribution to the plasma membrane. Through interactions with membrane lipids, it disrupts ionic homeostasis and membrane structure, ultimately causing cell swelling, increased plasma membrane permeability, and lysis. Phosphorylation of human MLKL is commonly monitored at Ser358, whereas Ser345 is commonly examined in mouse MLKL, reflecting species-specific differences in execution sites.

1.3 ZBP1 and Noncanonical RIPK3 Activation

(1) Recognition of Z-Conformation Nucleic Acids

ZBP1 contains Zα domains that can recognize nucleic acids in the Z conformation. During viral infection, disruption of endogenous nucleic-acid homeostasis, and certain tumor-stress conditions, ZBP1 can sense abnormal nucleic acids and activate RIPK3, with Z-RNA representing an important signal source in many physiological and antiviral contexts. Alterations in chromatin or nucleic-acid homeostasis can also increase Z-conformation nucleic acids, making ZBP1 an important sensing node connecting nucleic-acid abnormalities with cell death.

(2) Direct ZBP1–RIPK3 Connection

ZBP1 establishes a direct signaling connection with RIPK3 through RHIM domains, allowing RIPK3 to receive upstream death signals independently of RIPK1 and subsequently activate MLKL. The ZBP1–RIPK3–MLKL axis represents an important form of RIPK1-independent necroptosis and creates crosstalk among nucleic-acid sensing, innate immunity, and lytic cell death within the same signaling network.

2 Conversion of Necroptosis into Tumor Immune Signals

2.1 Immune Output of Lytic Cell Death

(1) DAMP Release

MLKL-mediated plasma membrane rupture can release HMGB1, ATP, and other intracellular danger signals into the extracellular environment. DAMPs can be sensed by local innate immune cells and alter the activation states of dendritic cells, macrophages, and other myeloid cells. Necroptosis therefore not only reduces cell numbers but also becomes a source of inflammatory signals within the tumor microenvironment.

(2) Tumor Antigen Exposure

Tumor-cell lysis simultaneously releases or exposes tumor-associated antigens, providing new antigen sources for antigen-presenting cells. DAMPs mainly provide danger signals, whereas tumor antigens provide targets for adaptive immune recognition. Whether these two signals are effectively coupled determines whether necroptosis is further converted into immunogenic cell death.

2.2 Dendritic Cells and Antigen Cross-Presentation

(1) Dendritic Cell Maturation

Necroptotic tumor cells can simultaneously provide antigens and inflammatory stimuli to dendritic cells, promoting their maturation and increasing expression of costimulatory molecules. Changes in DC status represent an important intermediate step connecting dying tumor cells with T-cell immunity.

(2) MHC-I Cross-Presentation

After dendritic cells take up exogenous antigens derived from dead tumor cells, some antigens can enter the MHC-I cross-presentation pathway, allowing tumor-derived antigens to be recognized by CD8+ T cells. Necroptosis can thereby expand from a local cell-death event into a signaling event capable of initiating tumor-specific adaptive immunity.

2.3 CD8+ T Cells and Establishment of Effector Immunity

(1) CD8+ T-Cell Priming

Following antigen presentation and costimulation, tumor-specific CD8+ T cells can further expand and be recruited into tumor tissues. Their effects are no longer restricted to cells that initially underwent necroptosis and can extend to tumor regions not directly exposed to the original death stimulus.

(2) Enhanced Effector Function

Effector CD8+ T cells entering tumor tissues can produce molecules such as IFN-γ and Granzyme B and enhance cytotoxicity against antigen-positive tumor cells. In some environments, NK cells and other innate effector cells can also respond to chemotactic and inflammatory signals generated by necroptosis, jointly altering local immune cytotoxic capacity.

2.4 Pre-Death Inflammatory Transcriptional Output

The immune effects of necroptosis do not depend entirely on cell lysis. RIPK1, RIPK3, and coupled pathways such as NF-κB can alter cytokine and chemokine expression before complete plasma membrane rupture, allowing cells approaching death to actively participate in shaping the inflammatory environment. MLKL-mediated lytic output primarily provides DAMPs and antigens, whereas pre-death transcription mainly affects immune-cell recruitment and local inflammatory signaling. Together, these processes determine the immunogenic intensity of necroptosis.

3 Bidirectional Effects of Necroptosis on the Tumor Microenvironment

3.1 Antitumor Effects

(1) Tumor-Cell Death and Antigen Supply

When tumor cells undergo necroptosis, they can simultaneously provide tumor antigens, DAMPs, and inflammatory chemotactic signals. In environments containing functional DCs and effector T cells, this process can enhance antigen cross-presentation and tumor-specific immunity and may provide an alternative cell-death pathway for tumors with defective apoptotic execution or partial treatment resistance.

(2) Expansion of Effector Immunity

Once the initial death event establishes effective antigen presentation, the participation of CD8+ T cells and other effector immune cells can expand, extending the effect from local tumor-cell death to broader tumor regions. In this setting, necroptosis not only directly reduces tumor-cell numbers but also promotes subsequent tumor clearance by the immune system.

3.2 Protumor or Immunosuppressive Effects

(1) Damage to Microenvironmental Cells

Necroptosis can occur in CAFs, endothelial cells, and immune cells. CAF death may weaken some tumor-supportive matrix and paracrine networks, whereas sustained necroptosis of endothelial cells or effector immune cells may impair vascular function, immune-cell infiltration, and local cytotoxicity. The identity of the dying cell type is therefore an important determinant of the final outcome.

(2) Sustained Inflammation and Myeloid Remodeling

Long-term, widespread lytic cell death can sustain the release of DAMPs and inflammatory mediators, promoting tissue-repair responses and persistent recruitment of myeloid cells. When an immunosuppressive myeloid environment gradually becomes dominant, inflammation itself no longer necessarily represents effective antitumor immunity and may instead contribute to tumor adaptation and immune escape.

3.3 Temporal and Spatial Dependence

The effects of necroptosis in tumors are also influenced by duration and spatial location. Short-term, focal necroptosis of tumor cells can generate concentrated and effective release of antigens and danger signals, whereas long-term lytic death in hypoxic necrotic regions is more likely to cause chronic tissue injury. The significance of necroptosis in tumors fundamentally depends on the cell type undergoing death, spatial location, duration, and local immune context.

4 RIPK3-Related Transcriptional Reprogramming and ZBP1 Signaling

4.1 RIPK3–TRIM28 and Immune Transcriptional Output

(1) TRIM28 Regulation

TRIM28 has transcriptional corepressor and chromatin-regulatory functions. In some tumor models, RIPK3 activation can affect the phosphorylation state of TRIM28 and its transcriptional repressive activity, thereby enhancing expression of certain immune-related genes that were previously restricted.

(2) Cytokine and Chemokine Output

Changes in TRIM28 regulation can further affect NF-κB-, SOX9-, and related transcriptional networks as well as cytokine and chemokine expression, allowing RIPK3 to participate in immune microenvironment remodeling beyond MLKL-mediated membrane rupture. RIPK3 therefore has dual roles as an upstream kinase in death execution and as a node in immune transcriptional regulation.

4.2 ADAR1–ZBP1 Signal Regulation

(1) ADAR1 Maintains Nucleic-Acid Immune Homeostasis

ADAR1 participates in double-stranded RNA editing and regulation of endogenous nucleic-acid immune homeostasis. Its p150 isoform contains a Zα domain and can limit aberrant nucleic-acid-related immune signaling. Intact ADAR1 function helps reduce the probability that endogenous nucleic acids continuously trigger innate immune sensing.

(2) Release of ZBP1 Signaling

When ADAR1-related protective mechanisms are reduced, abnormal nucleic-acid sensing is enhanced, making it easier for ZBP1 to engage the RIPK3 signaling node and, in cells with intact MLKL execution capacity, form ZBP1–RIPK3–MLKL-dependent necroptosis. ADAR1 therefore connects RNA homeostasis, Z-conformation nucleic-acid sensing, and susceptibility to necroptosis.

4.3 CBL0137 and ZBP1-Dependent Stromal Remodeling

CBL0137 is a FACT-related regulatory compound that, in certain systems, can increase Z-conformation nucleic-acid-related stress and activate ZBP1–RIPK3–MLKL signaling. In some tumor models, this effect can occur in stromal cells such as cancer-associated fibroblasts, altering the local immune environment by weakening supportive matrix and paracrine networks. This model illustrates that the antitumor effect of necroptosis does not necessarily arise from direct killing of tumor cells and can instead result from remodeling of the tumor stroma.

5 Necroptosis and Immune Checkpoint Blockade

5.1 Immune Basis of ICB Sensitivity

(1) Improved Antigen Presentation

Necroptosis can increase tumor-antigen exposure and danger signals, providing conditions for DC maturation and cross-presentation. Tumors with initially insufficient antigen release or low antigen-presentation efficiency may thereby develop a local immune environment more favorable to T-cell priming.

(2) Effector T-Cell Infiltration

Changes in chemokines and inflammatory signals can further promote CD8+ T-cell entry into tumor tissues, shifting tumors with limited effector lymphocyte infiltration toward a more immune-responsive state. In this context, ICB primarily relieves the inhibitory state of T cells that already exist or have been reactivated.

5.2 Bidirectional Outcomes of Combination with ICB

The potential synergy between necroptosis and ICB essentially combines enhanced immune priming with relief of effector-cell suppression. RIPK3–MLKL execution, ZBP1-related nucleic-acid sensing, tumor antigenicity, and the stromal environment can all influence the strength of this synergy. If necroptosis mainly causes sustained tissue lysis without improving antigen presentation or effector T-cell status, it is unlikely to translate into effective ICB sensitization.

6 Experimental Determination of Necroptosis

6.1 Core Evidence Chain

(1) Membrane Integrity and Dynamic Morphology

During necroptosis execution, cells can show swelling, increased plasma membrane permeability, and eventual membrane rupture. PI or 7-AAD uptake and LDH release can be used to evaluate progression of lytic cell death, while time-lapse live-cell imaging can further resolve the sequence of death events. These indicators are not specific for necroptosis and should be interpreted together with the status of the RIPK3–MLKL pathway.

(2) RIPK3–MLKL Activation

p-RIPK3 and p-MLKL more directly reflect pathway functional status than total RIPK3 and total MLKL. Combining p-MLKL detection with MLKL membrane translocation or oligomerization can further support progression into the execution stage. Increased total RIPK1, RIPK3, or MLKL protein expression alone cannot confirm that necroptosis has occurred.

(3) Pharmacological Rescue

RIPK1-dependent models can be validated using inhibitors such as Necrostatin-1 and Nec-1s, while RIPK3 inhibitors can be used to confirm RIPK3 dependence. Necrosulfonamide can be used to interfere with MLKL in certain human models. Different inhibitors have species selectivity, target differences, and potential off-target effects; pharmacological intervention at multiple pathway nodes can therefore improve the reliability of pathway attribution.

(4) Genetic Validation

If RIPK3 or MLKL knockdown/knockout simultaneously reduces p-MLKL, membrane rupture, and overall cell death, attribution to necroptosis is substantially strengthened. RIPK1 deficiency is mainly used to determine whether a model depends on RIPK1. In pathways where ZBP1 or TRIF directly engages RIPK3, lack of rescue by RIPK1 inhibition does not exclude necroptosis.

6.2 Differentiation from Other Forms of Cell Death

(1) Differentiation from Apoptosis

Marked increases in cleaved caspase-3, cleaved caspase-7, and cleaved PARP that are reduced by caspase inhibitors more strongly support caspase-dependent apoptosis. In some TNF-related models, inhibition of caspase-8 can promote RIPK1/RIPK3/MLKL-dependent necroptosis. Z-VAD-type inhibitors can therefore be used both to analyze apoptosis dependence and as part of conditions that induce necroptosis.

(2) Differentiation from Pyroptosis

Pyroptosis is generally accompanied by inflammatory caspase activation, GSDMD cleavage, and maturation of IL-1β/IL-18. Because both pyroptosis and necroptosis can show cell swelling, PI positivity, and LDH release, the GSDMD execution axis and RIPK3–MLKL execution axis should be examined separately. If both are activated, multiple forms of regulated cell death may be occurring in parallel.

(3) Differentiation from Ferroptosis

Ferroptosis should be assessed using indicators such as lipid ROS, GPX4, GSH, and ACSL4 together with rescue experiments using Ferrostatin-1, Liproxstatin-1, and related agents. Ferroptosis does not rely on RIPK3–MLKL activation or typical MLKL-mediated membrane rupture as its core execution mechanism.

(4) Differentiation from Unregulated Necrosis

Unregulated necrosis generally lacks a stable, specific execution signaling axis and more often results directly from severe physical, chemical, or metabolic injury. Specific activation of RIPK3–MLKL, lytic cell-death phenotypes, and pharmacological or genetic rescue together constitute the main basis for distinguishing necroptosis from general necrosis.

Table 2 Integrated Interpretation of Common Experimental Results in Necroptosis

Experimental Result	Interpretation
p-RIPK3↑, p-MLKL↑, LDH↑, and rescue by RIPK3/MLKL intervention	Strongly supports RIPK3–MLKL-dependent necroptosis
p-MLKL↑, but no obvious change in PI/LDH	MLKL signaling has been activated, but terminal membrane rupture has not yet occurred sufficiently
PI↑ and LDH↑, but no change in p-MLKL and no rescue by pathway intervention	Does not support necroptosis; other forms of lytic cell death should be considered
Cell death increases after Z-VAD treatment and is partially rescued by RIPK1 inhibition	Supports conversion toward RIPK1-dependent necroptosis after caspase inhibition
RIPK1 inhibition is ineffective, but RIPK3 or MLKL intervention rescues cell death	Consider RIPK1-independent RIPK3–MLKL activation
p-MLKL and cleaved GSDMD both increase	Multiple forms of regulated cell death may coexist and should be validated separately

6.3 Spatial Heterogeneity and Cellular Origin in Solid Tumors

(1) Regional Heterogeneity

Necroptosis in solid tumors is usually not uniformly distributed. Necrotic regions, hypoxic regions, invasive margins, perivascular regions, and immune-infiltrated areas may have different p-MLKL states. Whole-tumor Western blotting can dilute local signals when the proportion of positive regions is low. H&E, p-MLKL immunohistochemistry, or immunofluorescence can be combined to provide spatial localization.

(2) Cellular Origin

p-MLKL signals in tumor tissues may originate from tumor cells, CAFs, endothelial cells, or immune cells, and necroptosis in different cell populations has different immune consequences. Colocalization with cell-type markers can be used, and cell sorting, regional sampling, or microdissection may be required to further determine signal origin.

(3) Temporal Sequence

RIPK3 activation, MLKL phosphorylation, membrane rupture, and secondary immune changes occur sequentially. Early signaling readouts, intermediate membrane damage, and later DC and T-cell changes should not be substituted by a single time point. This is particularly important when analyzing causal relationships between necroptosis and tumor immunity, where death initiation, execution, and secondary immune remodeling should be distinguished.

7 Products Related to Necroptosis Pathway Intervention, Cell Death Discrimination, and Detection

7.1 RIPK1-, RIPK3-, MLKL-, and Caspase-Related Intervention Products

Catalog #	Product Name	Grade & Purity	Research Positioning
N125522	Necrostatin-1	Moligand™, ≥99%	Inhibition of RIPK1-related necroptosis and validation of RIPK1 dependence
G414090	GSK'963	Moligand™, ≥98%	Intervention in RIPK1 kinase-related death signaling
C275378	7-Cl-O-Nec1	Moligand™, ≥98%	RIPK1 inhibition and validation of RIPK1 kinase-dependent necroptosis
R413493	RIPA-56	Moligand™, ≥98%	Determination of RIPK1 kinase-activity dependence
N646261	Necrostatin 2	≥99%	Inhibition of RIPK1-related necroptosis and pharmacological control
G409176	GSK'872 (GSK2399872A)	10mM in DMSO	RIPK3 functional inhibition and validation of RIPK3 dependence
G579356	GSK'843	Moligand™, ≥98%	RIPK3-related necroptosis research
N408273	Necrosulfonamide	10mM in DMSO	Validation of the human MLKL-related necroptosis execution stage
M651796	MLKL-IN-2	≥99%	MLKL inhibition and research on the necroptosis execution node
Z421947	Z-VAD(OH)-FMK (Caspase Inhibitor VI)	10mM in DMSO	Broad-spectrum caspase blockade for analysis of apoptosis dependence and cell-death switching
V275259	Z-VAD(OMe)-FMK	Moligand™, ≥98%	Cell-permeable pan-caspase inhibition and research on necroptosis-inducing conditions
Q275003	QVD-OPh	≥95%, mixture of isomers	Broad-spectrum caspase inhibition for independent validation of caspase dependence
M274709	Caspase-3/7 Inhibitor	≥97%	Inhibition of effector caspase-3/7 to help distinguish apoptotic execution from necroptosis

7.2 Products for Cell Death Discrimination and Exclusion Controls

Catalog #	Product Name	Grade & Purity	Research Positioning
S102392	Staurosporine	Moligand™, ≥98%	Classical apoptosis-induction control for distinguishing caspase-dependent cell death
F129882	Ferrostatin-1 (Fer-1)	Moligand™, ≥99%	Inhibition of lipid peroxidation for exclusion of ferroptosis-related mechanisms
L413818	Liproxstatin-1	Moligand™, ≥97%	Ferroptosis inhibitor providing independent exclusion evidence together with Ferrostatin-1
A1456543	7-AAD Cell Cycle and Apoptosis Analysis Kit	sterile-filtered, Suitable for Immunofluorescence (IF), BioReagent, ready-to-use, Biological Stain, for fluorescence analysis, for microscopy, for cell culture, for DNA and RNA applications	Combined evaluation of cell-cycle status and proportion of dead cells
A1372406	7-AAD Viability Staining Solution	sterile-filtered, Suitable for Immunofluorescence (IF), BioReagent, ready-to-use, Biological Stain, for fluorescence analysis, Biological dye grade, for microscopy, for cell culture, sterile, 0.1 mg/mL, 2.5μL/test	Detection of viable and dead cells based on membrane integrity
A1373481	Annexin V-EGFP/PI Apoptosis Detection Kit	BioReagent, ready-to-use, for fluorescence analysis, Suitable for Analysis, for detection	Differentiation of Annexin V-positive and PI-positive states to assist assessment of apoptosis and terminal membrane rupture
E1520241	All-in-One Apoptotic, Necrotic and Healthy Cell Comprehensive Status Enhanced Detection Kit (Annexin V-R-PE, Draq 7, Hoechst 33342)	BioReagent, Biological Stain, for fluorescence analysis, for microscopy, sterile	Simultaneous discrimination of healthy, apoptotic, and membrane-integrity-lost cell populations
C1372489	Caspase 3/7 Activity Assay Kit	BioReagent	Measurement of caspase-3/7 activity as a functional readout of the apoptotic execution axis
L1520214	Live Cell Caspase-3/7 Activity and Annexin V Dual Apoptosis Detection Kit (LumiDye™ 488 Caspase-3/7, LumiDye™ 594-Annexin V, Hoechst 33342)	BioReagent, sterile, for microscopy, Biological Stain, for fluorescence analysis	Simultaneous live-cell analysis of caspase activation and phosphatidylserine externalization
L1520218	Live Cell Caspase-3/7 Activity and Annexin V Dual Apoptosis Detection Kit (LumiDye™ 488 Caspase-3/7, LumiDye™ 647-Annexin V, EthD Gold, Hoechst 33342)	BioReagent, sterile, for microscopy, Biological Stain, for fluorescence analysis	Multiparametric cell-death interpretation combining caspase activity, Annexin V, and membrane permeability

7.3 Products for Membrane Rupture, Cell Viability, and Key Pathway Protein Detection

Catalog #	Product Name	Grade & Purity	Research Positioning
P266304	Propidium iodide（PI）	≥98%(HPLC)	Detection of increased plasma membrane permeability and terminal cell death
A131295	7-Aminoactinomycin D	Moligand™, ≥97%(HPLC)	Flow-cytometric detection of loss of membrane integrity and proportion of dead cells
C266180	Cell Counting Kit-8	BioReagent, for detection	Evaluation of overall cell viability after induction or inhibition treatment
L1501762	Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (WST-8, Micro Method)	BioReagent	Detection of extracellular LDH release to evaluate lytic membrane damage
L1521751	Lactate Dehydrogenase (LDH) Activity Assay Kit (LD-P, UV Colorimetric Method)	BioReagent	LDH activity detection
Ab125400	Recombinant RIP Antibody	Recombinant, ExactAb™, Validated, See COA	Detection of total RIPK1 protein to evaluate pathway expression background
Ab125423	RIP3 Mouse mAb	Carrier Free, ExactAb™, Validated, 0.5 mg/mL	Detection of total RIPK3 protein to evaluate baseline RIPK3 expression
Ab213595	Caspase 3 Mouse mAb	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, PBS Only, ≥95%(SDS-PAGE), 1.0 mg/mL	Detection of caspase-3 to support establishment of apoptosis controls
Ab326059	Cleaved Caspase 8 Antibody	KD Validation	Detection of caspase-8 cleavage status to evaluate death-receptor-related apoptotic signaling
Ab326939	Recombinant cleaved Caspase-9 Antibody	KD Validation	Detection of caspase-9 activation related to the mitochondrial apoptotic pathway
Ab106592	GSDMD Antibody	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA	Detection of GSDMD as an indicator for exclusion or parallel validation of the pyroptosis execution axis
Ab327478	Recombinant Gasdermin D Antibody	KO Validation	GSDMD protein detection and pyroptosis-pathway validation

Necroptosis links lytic cell death, DAMP and tumor-antigen release, inflammatory transcription, and immune-cell remodeling through RIPK1- or ZBP1-mediated activation of the RIPK3–MLKL axis. Its effects in tumors depend on the identity of dying cells, spatial location, duration, and local immune context. It can initiate antigen presentation and effector immunity, but it can also evolve into persistent inflammation and an immunosuppressive microenvironment.

References

[1] Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: Mechanisms and Relevance to Disease. Annu Rev Pathol. 2017;12:103-130.

[2] Aaes TL, Kaczmarek A, Delvaeye T, et al. Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity. Cell Rep. 2016;15(2):274-287.

[3] Park HH, Kim HR, Park SY, et al. RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol Cancer. 2021;20(1):107.

[4] Zhang T, Yin C, Fedorov A, et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. 2022;606(7914):594-602.

For more related articles, please see below:

[1] Experiments for the morphological evaluation of cell death

[2] Experiments on biochemical analysis of cell death

[3] Staining Principles and Methods for Cell Death, Proliferation, and Metabolic Viability

[4] Apoptosis detection by AO staining (Amino Orange Stain)

[5] Cytokines and Inflammation

[6] Microscopic morphologic observation of apoptosis

[7] How NKG2A and NKG2D Jointly Regulate Tumor Immune Killing

[8] Study of the CD161-LLT1 Immune Regulatory Axis: Evaluation of Tumor Immunity, NK Cell Function, and T Cell Responses

[9] How Does Dynamic ECM Remodeling in the Tumor Microenvironment Regulate Tumor Immune Responses?